Published in Neoplasia on May 01, 2006
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
Tumor cell migration in complex microenvironments. Cell Mol Life Sci (2012) 1.16
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells. BMC Biophys (2013) 0.90
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget (2015) 0.77
Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. Am J Hum Genet (2015) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Res (2017) 0.75
Mimp/Mtch2, an Obesity Susceptibility Gene, Induces Alteration of Fatty Acid Metabolism in Transgenic Mice. PLoS One (2016) 0.75
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol (2017) 0.75
'Green mice' as a source of ubiquitous green cells. FEBS Lett (1997) 17.06
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39
The organ microenvironment and cancer metastasis. Differentiation (2002) 2.81
The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol Cell Biol (1990) 2.80
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol (1992) 2.53
Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res (1997) 2.30
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (1997) 2.12
Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res (1994) 1.99
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
The Met proto-oncogene mesenchymal to epithelial cell conversion. Science (1994) 1.77
GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res (2002) 1.77
The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A (1998) 1.76
Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer (1998) 1.75
c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res (1998) 1.54
Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (1997) 1.50
Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene (2003) 1.41
Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ (1996) 1.36
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A (2004) 1.31
Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res (2005) 1.29
Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ (1993) 1.27
Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem (1994) 1.26
Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26
Being in the right location at the right time. Genome Biol (2001) 1.21
A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Exp Cell Res (1998) 1.19
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene (1992) 1.16
The color of mice: in the light of GFP-variant reporters. Histochem Cell Biol (2001) 1.14
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. Mol Carcinog (2004) 1.13
Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer (2002) 1.05
Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp Cell Res (2004) 1.04
Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int (1998) 1.03
The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene (1999) 1.02
HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia (2001) 0.97
Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol (2004) 0.96
Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci (2003) 0.95
Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem Biophys Res Commun (2000) 0.94
Feasibility, sensitivity, and reliability of laser-induced fluorescence imaging of green fluorescent protein-expressing tumors in vivo. Mol Ther (2003) 0.91
Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol (1999) 0.90
CMV-driven expression of green fluorescent protein (GFP) in male germ cells of transgenic mice and its effect on fertility. Int J Androl (2001) 0.89
Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. Cancer Metastasis Rev (1991) 0.89
Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology (1998) 0.88
Met-HGF/SF signal transduction induces mimp, a novel mitochondrial carrier homologue, which leads to mitochondrial depolarization. Neoplasia (2002) 0.87
Structural and functional characterization of the mouse c-met proto-oncogene (hepatocyte growth factor receptor) promoter. Biochim Biophys Acta (1998) 0.82
Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. Cytometry (2000) 0.81
Vascular networks and endothelial cells in the rat experimental pituitary glands and in the human pituitary adenomas. Microsc Res Tech (2003) 0.80
Mammary fibroblast-derived hepatocyte growth factor and mammogenic hormones stimulate the growth of mouse mammary epithelial cells in primary culture. Endocr J (1999) 0.80
Role of incipient angiogenesis in cancer metastasis. Cancer Metastasis Rev (2000) 0.79
Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate (2005) 0.78
Sebaceous gland and sweat gland carcinomas of the skin. Clinicopathological study and significance of c-erbB-2 oncoprotein expression. Acta Pathol Jpn (1992) 0.76
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Detection of protein-protein interactions in plants using bimolecular fluorescence complementation. Plant J (2004) 3.47
PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol (2011) 3.22
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell (2005) 2.91
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol (2005) 2.58
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res (2004) 2.46
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A (2007) 2.15
HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08
Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res (2006) 1.94
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A (2006) 1.85
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res (2008) 1.76
The decline in U.S. cancer mortality in people born since 1925. Cancer Res (2009) 1.61
HGF/SF-Met signaling in tumor progression. Cell Res (2005) 1.61
Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal (2011) 1.58
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Archived unfrozen neonatal blood spots are amenable to quantitative gene expression analysis. Neonatology (2008) 1.51
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene (2002) 1.47
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
INDI: a computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol (2012) 1.40
Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A (2005) 1.40
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A (2002) 1.38
Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene (2004) 1.37
Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res (2007) 1.33
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
RhoB and the mammalian Diaphanous-related formin mDia2 in endosome trafficking. Exp Cell Res (2006) 1.29
Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A (2009) 1.28
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res (2010) 1.28
Mig-6, signal transduction, stress response and cancer. Cell Cycle (2007) 1.28
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene (2005) 1.25
Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia (2008) 1.24
The analysis of protein-protein interactions in plants by bimolecular fluorescence complementation. Plant Physiol (2007) 1.22
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A (2005) 1.16
RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res (2004) 1.15
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15
Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res (2012) 1.13
PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol (2005) 1.13
The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int J Cancer (2011) 1.11
Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res (2007) 1.10
The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia (2006) 1.09
Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis (2012) 1.09
Gene expression in rat lacrimal gland duct cells collected using laser capture microdissection: evidence for K+ secretion by duct cells. Invest Ophthalmol Vis Sci (2006) 1.08
Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med (2012) 1.07
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene (2005) 1.06
Emergence of HGF/SF-induced coordinated cellular motility. PLoS One (2012) 1.06
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A (2011) 1.05
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog (2007) 1.05
Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI. Sci Rep (2013) 1.04
In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One (2011) 1.04
A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med (2008) 1.03
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem (2011) 1.01
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther (2008) 1.00
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98
VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res (2010) 0.98
Cell motility dynamics: a novel segmentation algorithm to quantify multi-cellular bright field microscopy images. PLoS One (2011) 0.98
Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab. J Thorac Oncol (2012) 0.98
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
Prospects for vasculature reorganization in sentinel lymph nodes. Cell Cycle (2007) 0.95
Functional MR imaging during hypercapnia and hyperoxia: noninvasive tool for monitoring changes in liver perfusion and hemodynamics in a rat model. Radiology (2007) 0.94
Functional analysis of Arabidopsis postprenylation CaaX processing enzymes and their function in subcellular protein targeting. Plant Physiol (2008) 0.94
A method for inferring medical diagnoses from patient similarities. BMC Med (2013) 0.93
Engraftment and differentiation of human metanephroi into functional mature nephrons after transplantation into mice is accompanied by a profile of gene expression similar to normal human kidney development. J Am Soc Nephrol (2002) 0.93
Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol Lett (2009) 0.93
K-Ras4B proteins are expressed in the nucleolus: Interaction with nucleolin. Biochem Biophys Res Commun (2006) 0.93
Mechanical contributions to astrocyte adhesion using a novel in vitro model of catheter obstruction. Exp Neurol (2010) 0.92
Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice. Neoplasia (2011) 0.91
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther (2009) 0.91
Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A (2014) 0.91
A mouse model of activating Met mutations. Cell Cycle (2005) 0.91
MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res (2013) 0.90
Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res (2005) 0.89
Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res (2006) 0.88
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin Cancer Res (2007) 0.88
Toward development of targeted nonsteroidal antiandrogen-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-gadolinium complex for prostate cancer diagnostics. J Med Chem (2010) 0.88
Functional molecular imaging of tumors by chemical exchange saturation transfer MRI of 3-O-Methyl-D-glucose. Magn Reson Med (2014) 0.88
Internal anal sphincter function following lateral internal sphincterotomy for anal fissure: a long-term manometric study. Ann Surg (2005) 0.88
Met-HGF/SF signal transduction induces mimp, a novel mitochondrial carrier homologue, which leads to mitochondrial depolarization. Neoplasia (2002) 0.87
The echogenicity of the normal fetal kidneys during different stages of pregnancy determined objectively. Arch Gynecol Obstet (2010) 0.87
An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med (2006) 0.86
Met decoys: will cancer take the bait? Cancer Cell (2004) 0.86
Referenceless reconstruction of spatiotemporally encoded imaging data: principles and applications to real-time MRI. Magn Reson Med (2014) 0.86
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Clin Cancer Res (2008) 0.86